.After a couple of years in biotech, Mike Quigley, Ph.D., is coming back to the pharma layer, using up the leading scientific research area at Sanofi.Quigley is going to start Sept. 30 as the French Big Pharma’s main clinical officer and also global director of investigation, Sanofi told Ferocious Biotech in an emailed claim.Quigley is switching out Frank Nestle, M.D., that left Sanofi this spring amid a worldwide overhaul of the business’s R&D unit. Nestle, that devoted eight years along with the pharma, hopped over to Deerfield Management, where he presently works as a partner on the rehabs team and also chief executive officer of the agency’s healing exploration and also advancement operations.
Quigley will certainly sign up with Sanofi from a San Francisco-based biotech that resides in stealth, according to his LinkedIn account. He is actually presently noted as the business’s founder, head of state and also CEO.Due to the fact that August 2021, Quigley has served as a venture companion at SV Health and wellness Investors, a healthcare fund supervisor along with present financial investments in biotechs including BioAge, Cerevance, Dualitas Rehabs as well as Nimbus Therapeutics, to name a few. Quigley in the past kept the top location at Dualitas, a biotech that remains in stealth, depending on to STAT.The soon-to-be Sanofi leader also formerly helmed Therini Biography, an immunotherapy biotech working to create treatments for neurodegenerative illness steered by general dysfunction.Before spending the last couple of years in biotech, Quigley possesses an even longer track record in Major Pharma, most recently working as Gilead’s senior bad habit head of state of research biology until the summer season of 2021.
Prior to that, he clocked in more than 4 years around numerous management functions at Bristol Myers Squibb as well as acted as a scientific supervisor at Johnson & Johnson’s Janssen upper arm just before that.Sanofi claimed Quigley’s purpose in his brand new duty will be to “optimize our likelihood of effectiveness by means of optimum cooperations throughout our institution and also beyond, bringing best-in-class technology and also cultivating as well as sourcing brand new industry-leading ability with a commitment to variety,” according to an interior memo obtained by STAT.